Connor Clark & Lunn Investment Management Ltd. Sells 48,460 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Connor Clark & Lunn Investment Management Ltd. reduced its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 7.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 633,864 shares of the biotechnology company’s stock after selling 48,460 shares during the period. Connor Clark & Lunn Investment Management Ltd.’s holdings in BioCryst Pharmaceuticals were worth $4,767,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of BCRX. Fisher Asset Management LLC increased its stake in BioCryst Pharmaceuticals by 16.9% in the third quarter. Fisher Asset Management LLC now owns 3,338,062 shares of the biotechnology company’s stock valued at $25,369,000 after purchasing an additional 481,359 shares in the last quarter. BNP Paribas Financial Markets increased its position in shares of BioCryst Pharmaceuticals by 472.0% during the third quarter. BNP Paribas Financial Markets now owns 496,784 shares of the biotechnology company’s stock worth $3,776,000 after acquiring an additional 409,938 shares in the last quarter. Principal Financial Group Inc. increased its position in shares of BioCryst Pharmaceuticals by 1,058.1% during the third quarter. Principal Financial Group Inc. now owns 411,414 shares of the biotechnology company’s stock worth $3,127,000 after acquiring an additional 375,890 shares in the last quarter. Cinctive Capital Management LP bought a new stake in shares of BioCryst Pharmaceuticals during the third quarter worth about $2,082,000. Finally, Two Sigma Advisers LP increased its position in shares of BioCryst Pharmaceuticals by 13.6% during the third quarter. Two Sigma Advisers LP now owns 2,181,012 shares of the biotechnology company’s stock worth $16,576,000 after acquiring an additional 261,500 shares in the last quarter. 85.88% of the stock is owned by institutional investors.

BioCryst Pharmaceuticals Stock Performance

Shares of BCRX stock opened at $7.70 on Monday. BioCryst Pharmaceuticals, Inc. has a 52-week low of $4.03 and a 52-week high of $9.50. The company has a 50-day simple moving average of $8.14 and a two-hundred day simple moving average of $7.85. The company has a market capitalization of $1.61 billion, a price-to-earnings ratio of -12.62 and a beta of 1.85.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its earnings results on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.06). The business had revenue of $131.50 million for the quarter, compared to analysts’ expectations of $126.64 million. The firm’s revenue was up 40.8% on a year-over-year basis. During the same quarter last year, the firm posted $0.28 EPS. On average, sell-side analysts forecast that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the stock. JMP Securities reissued a “market outperform” rating and set a $18.00 target price on shares of BioCryst Pharmaceuticals in a research report on Friday, January 31st. Evercore ISI boosted their target price on shares of BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the stock an “outperform” rating in a research report on Monday, January 13th. HC Wainwright reissued a “buy” rating and set a $30.00 target price on shares of BioCryst Pharmaceuticals in a research report on Tuesday, February 25th. Royal Bank of Canada reissued an “outperform” rating and set a $11.00 target price (up from $10.00) on shares of BioCryst Pharmaceuticals in a research report on Tuesday, February 25th. Finally, Needham & Company LLC upped their price objective on shares of BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the stock a “buy” rating in a research report on Monday, January 13th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $15.57.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.